Simultaneous reduction of amyloid beta and phosphorylated tau for Alzheimer’s Disease with Chemically Optimized Stringed Modifiable Oligonucleotides (COSMOs)
To date, there are no approved therapeutics for AD capable of reducing both A𝛣 and p-Tau. Oligonucleotide therapeutics for AD have shown early clinical success in reducing either A𝛣 or p-Tau, but not both. COSMOs are a promising new class of therapeutics capable of reducing both A𝛣 and p-Tau for AD.
Authors
- Jack Stahl (ORCID: https://orcid.org/0000-0002-1081-6404)
- Olga Khorkova (ORCID: https://orcid.org/0000-0002-1848-2365)
- Claes Wahlestedt (ORCID: https://orcid.org/0000-0003-4471-5916)
- Claude‐Henry Volmar (ORCID: https://orcid.org/0000-0001-9437-051X)
- Aswathy Joji
- Elianny Perozo Rojas
Institutions
- University of Miami (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70859_103402
- Primary Topic
- RNA Interference and Gene Delivery
- Type
- article
- Field-Weighted Citation Impact
- 0.00